Engineered immune cells take on tough blood cancers in early trial
NCT ID NCT07109518
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase study is testing a new type of immune cell therapy called universal CD7 CAR-T (uCD7 CART) in people with relapsed or refractory acute myeloid leukemia (AML) or T-cell leukemia/lymphoma. The cells are designed to target and kill cancer cells that carry the CD7 protein. Up to 12 participants will receive the treatment after a short course of chemotherapy, and researchers will monitor safety and how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Universal CD7 CAR-T cells (uCD7 CART) given after chemotherapy conditioning
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat blood cancers that express CD7.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, so it is too small to prove effectiveness. There are also risks of severe side effects from the CAR-T cells or the chemotherapy given beforehand.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact